George Ansstas

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

Drug Administration

Top Venues

Pharmaceuticals (Basel, Switzerland)

Cancer immunology, immunotherapy : CII

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

George Nassief, Angela Anaeme, Karen Moussa, David Chen, George Ansstas
Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies? Pharmaceuticals (Basel, Switzerland) 17 (7) (2024)
George Nassief, Angela Anaeme, Karen Moussa, David Chen, George Ansstas
Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies? Pharmaceuticals (Basel, Switzerland) 17 (7) (2024)
Jordan Phillipps, George Nassief, Renee Morecroft, Tolulope Adeyelu, Andrew Elliott, Farah Abdulla, Ari M VanderWalde, Soo Park, Omar Butt, Alice Zhou, George Ansstas
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma. NPJ precision oncology 8 (1) (2024)
George Nassief, Angela Anaeme, Karen Moussa, David Chen, George Ansstas
Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies? Pharmaceuticals (Basel, Switzerland) 17 (7) (2024)
Helen Hwang, Jiayi Huang, Karam Khaddour, Omar H Butt, George Ansstas, Jie Chen, Ruth Gn Katumba, Albert H Kim, Eric C Leuthardt, Jian L Campian
Prolonged response of recurrent IDH -wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab. CNS oncology 11 (1) (2022)
Pashtoon Murtaza Kasi, Sakti Chakrabarti, Sarah Sawyer, Michael Krainock, Andrew Poklepovic, George Ansstas, Minu Maninder, Meenakshi Malhotra, Joe Ensor, Ling Gao, Zeynep Eroglu, Sascha Ellers, Paul Billings, Angel Rodriguez, Alexey Aleshin
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. BMJ open 12 (5) (2022)
Karam Khaddour, Sangeeta Khanna, Michael Ansstas, Ishaan Jakhar, Sonika Dahiya, Laurin Council, George Ansstas
Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma. Cancer immunology, immunotherapy : CII 70 (9) (2021)
Karam Khaddour, Ilana S Rosman, Farrokh Dehdashti, George Ansstas
Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy? The Journal of dermatology 48 (2) (2020)